US EditionTrump signs order to boost domestic drug manufacturing as pharma tariff threat looms
- President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S., streamlining the path for pharmaceutical companies to build new production sites.
- The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S., as the U.S. Imported $203 billion in pharmaceutical products in 2023.
- Some pharmaceutical companies are pushing back on Trump's plans, as reshoring manufacturing could elevate production costs and drug prices, raising affordability concerns.
23 Articles
23 Articles
Trump signs executive order to encourage US drug manufacturing
U.S. President Donald Trump signed an executive order on Monday that aims to reduce the time it takes to approve pharmaceutical plants in the country, as part of new regulations to encourage domestic manufacturing.
Trump signs executive order aimed at boosting US prescription drug manufacturing
President Donald Trump signed an executive order on Monday to cut down on the time it takes to approve U.S. pharmaceutical plants and to encourage more U.S. manufacturing of prescription drugs.
Trump Signs Order to Boost US Drug Manufacturing Ahead of Potential Pharma Tariffs
WASHINGTON—President Donald Trump on Monday signed an executive order aimed at boosting domestic production of prescription drugs and reducing America’s dependence on foreign pharmaceutical supply chains. The order directs the Food and Drug Administration (FDA) to streamline the approval process for domestic manufacturing facilities by eliminating unnecessary regulations and accelerating reviews. A key focus is cutting red tape within the permit…
Coverage Details
Bias Distribution
- 56% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
